Valirx plc (VAL) ORD GBP0.001
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
ValiRx inks deal with Dundee Drug Discovery Unit
12 February 2024 12:59
(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.
-
ValiRx enters option deal with Ambrose Healthcare
5 December 2023 15:08
(Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private...
-
ValiRx enters partnership with StingRay Bio
10 November 2023 10:32
(Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.
-
ValiRx shares jump as H1 losses shrink
24 August 2023 09:59
(Sharecast News) - Shares in ValiRx jumped nearly on Thursday after the biotech posted results for its first half, in which losses per share shrunk by a third.
-
ValiRx subsidiary Inaphaea signs deal with Agility Life Sciences
14 August 2023 09:53
(Sharecast News) - Life science company ValiRx announced on Monday that its wholly-owned subsidiary Inaphaea BioLabs has entered a collaborative services agreement with Agility Life Sciences.
-
ValiRx terminates collaboration with Hokkaido University
16 June 2023 11:14
(Sharecast News) - Life science company ValiRx has officially concluded its evaluation agreement with Hokkaido University, it announced on Friday.
-
ValiRx acquires assets of in-liquidation Imagen Therapeutics
14 June 2023 14:37
(Sharecast News) - Life science company ValiRx has successfully completed the acquisition of the scientific assets of Imagen Therapeutics, it announced on Wednesday.
-
ValiRx incorporates new wholly-owned lab subsidiary
1 March 2023 14:26
(Sharecast News) - Life science company ValiRx announced the incorporation of a new wholly-owned subsidiary, Inaphaea BioLabs, on Wednesday.
-
ValiRx forms new majority-owned breast cancer subsidiary
24 October 2022 12:47
(Sharecast News) - Women's health and cancer therapeutics company ValiRx announced the formation of a new partially-owned subsidiary, Cytolytix, on Monday, which had signed an intellectual property...
-
ValiRx expecting to grant extension of exclusivity to TheoremRx
17 June 2022 13:55
(Sharecast News) - Cancer therapeutics and women's health-focussed ValiRx updated the market on its proposed sub-licensing agreement with TheoremRx for 'VAL201' on Friday.
-
ValiRx amends longstanding licence deal with Cancer Research Technology
20 December 2021 12:17
(Sharecast News) - Cancer therapeutics developer ValiRx announced on Monday that it has amended and restated the licence for the VAL201 peptide held by the company from Cancer Research Technology (CRT) to...
-
ValiRx adds three new patents in first half
6 July 2021 13:00
(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it had continued to build its intellectual property position in the...
Company announcements Announcements
-
Directorate Changes
22 April 2024 07:00
Valirx
-
Evaluation Agreement with Imperial College London
21 March 2024 07:00
Valirx
-
Board Re-structuring and update on requisition
19 March 2024 07:00
Valirx
-
Shareholder Requisition Notice
4 March 2024 17:47
Valirx
-
Proposed Appointment of Non-Executive Director
4 March 2024 07:00
Valirx
-
Proposed Appointment of Non-Executive Director
29 February 2024 14:00
Valirx
-
Further re Shareholder Requisition Notice
13 February 2024 14:20
Valirx
-
Shareholder Requisition Notice
9 February 2024 17:06
Valirx
-
Change of Broker
19 January 2024 07:00
Valirx
-
Directorate Change
18 January 2024 07:00
Valirx
-
Result of GM, Issue of Equity
4 January 2024 13:48
Valirx
-
Result of Retail Offer, Subscription
19 December 2023 18:11
Valirx
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.